1.A Case of Cholesterosis Bulbi with Secondary Glaucoma Treated by Vitrectomy and Intravitreal Bevacizumab.
Jongseok PARK ; Hoyoung LEE ; Young Kook KIM ; Jeong Don CHAE ; Hyun Joo LEE
Korean Journal of Ophthalmology 2011;25(5):362-365
We report on a case of cholesterosis bulbi concurrent with secondary glaucoma. A 36-year-old man, with a history of long-standing retinal detachment in his right eye after the irrigation and aspiration of a congenital cataract, presented with a clinical picture of elevated intraocular pressure and ocular pain. Upon slit-lamp examination, we found a ciliary injection and a pseudohypopyon of polychromatic crystals. Gonioscopic examination revealed a large amount of crystals deposited on the trabecular meshwork and mild rubeosis iridis, but the neovascularization of the angle could not be clearly confirmed due to the presence of so many crystals. Pars plana vitrectomy was performed to remove clusters of crystals and bevacizumab was injected intravitreally to treat iris neovascularization. Aqueous aspirate was examined by light microscopy and the typical highly refringent cholesterol crystals were identified. Intraocular pressure returned to a normal level after the bevacizumab injection, although severe cholesterosis was still evident in the anterior chamber. To our knowledge, this would be the first Korean case of cholesterosis bulbi combined with chronic retinal detachment and presumed neovascular glaucoma, which was treated by pars plana vitrectomy and intravitreal bevacizumab injection.
Adult
;
Angiogenesis Inhibitors/therapeutic use
;
Anterior Chamber/*metabolism
;
Antibodies, Monoclonal, Humanized/*therapeutic use
;
*Cholesterol
;
Eye Diseases/complications/metabolism
;
Follow-Up Studies
;
Glaucoma/surgery
;
Glaucoma, Neovascular/drug therapy/*etiology/surgery
;
Humans
;
Intraocular Pressure
;
Male
;
Vitrectomy/*methods
2.Intravitreal Bevacizumab for the Treatment of Neovascular Glaucoma Associated With Central Retinal Artery Occlusion.
Min SAGONG ; Jinseon KIM ; Woohyok CHANG
Korean Journal of Ophthalmology 2009;23(3):215-218
We report three cases of neovascular glaucoma secondary to central retinal artery occlusion (CRAO) which were effectively managed with intravitreal bevacizumab (IVB) followed by panretinal photocoagulation (PRP). Neovascular glaucoma without peripheral anterior synechiae developed between one and five weeks following CRAO onset. All patients received 0.75 mg (0.03 ml) IVB. In all patients, complete regression of the iris and anterior chamber angle neovascularization was confirmed within one week. PRP was applied two weeks after the injection. The follow-up period was four to seven months (average, five months). Intraocular pressure was controlled in all patients using topical antiglaucoma medications alone. However, one patient experienced a recurrence of neovascularization three months after the initial combination treatment. This patient received another IVB injection and additional PRP, and the recurrent neovascularization resolved. There were no local or systemic adverse events in any patients. Therefore, intravitreal bevacizumab may be an effective adjunct in the treatment of neovascular glaucoma associated with CRAO.
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Female
;
Glaucoma, Neovascular/*drug therapy/*etiology
;
Humans
;
Injections
;
Male
;
Middle Aged
;
Recurrence
;
Retinal Artery Occlusion/*complications
;
Retreatment
;
Treatment Outcome
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Vitreous Body
3.Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series.
Jin Young CHOI ; Jaewan CHOI ; Yeon Deok KIM
Korean Journal of Ophthalmology 2010;24(1):47-52
This prospective observational case series study included 6 eyes of 6 consecutive glaucomatous patients. Each patient underwent trabeculectomy with mitomycin C, and received a 1.25 mg of subconjunctival bevacizumab injection at completion of the trabeculectomy. Study eyes included two with neovascular glaucoma, three with uveitic glaucoma, and one with secondary glaucoma following vitrectomy. All eyes had undergone failed glaucoma laser/surgical treatment or an intraocular surgical procedure. Intraocular pressure (IOP) at the following postoperative visits: preoperative, 1 week, 1 month, 2 months, 3 months, and 6 months, was measured. We also evaluated postoperative bleb findings and complications. IOP measured at each visit was 37.5+/-14.4 mmHg, 6.2+/-3.4 mmHg, 8.3+/-7.2 mmHg, 12.0+/-4.4 mmHg, 10.8+/-3.1 mmHg, and 12.2+/-3.3 mmHg, respectively, for each visit. All eyes had functioning blebs with normal IOP at postoperative 6 months with no additional IOP-lowering medication.
Adult
;
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Conjunctiva
;
Female
;
Glaucoma/*drug therapy/etiology/*surgery
;
Glaucoma, Neovascular/drug therapy/surgery
;
Humans
;
Injections, Intraocular
;
Male
;
Middle Aged
;
Prospective Studies
;
Trabeculectomy/*methods
;
Uveitis/complications
;
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
;
Vitrectomy/adverse effects
4.Progression of Impending Central Retinal Vein Occlusion to the Ischemic Variant Following Intravitreal Bevacizumab.
Korean Journal of Ophthalmology 2010;24(3):179-181
A 60-year-old woman who had experienced two episodes of amaurosis fugax in her right eye presented with vision loss. Two weeks earlier, at a private clinic, she was diagnosed with impending central retinal vein occlusion (CRVO) of the right eye and received an intravitreal injection of bevacizumab. Two weeks after this injection she was diagnosed with ischemic CRVO. At 11-weeks post-presentation, extremely ischemic features were observed with fluorescein angiographic findings of severe vascular attenuation and extensive retinal capillary obliteration. At 22-weeks post-presentation she was diagnosed with neovascular glaucoma; she experienced no visual improvement over the following several months.
Antibodies, Monoclonal/*administration & dosage
;
Disease Progression
;
Female
;
Fluorescein Angiography
;
Glaucoma, Neovascular/complications
;
Humans
;
Injections, Intraocular
;
Ischemia/diagnosis/*etiology/physiopathology
;
Middle Aged
;
Retinal Vein Occlusion/*complications/*drug therapy/physiopathology
;
*Retinal Vessels
;
Vascular Endothelial Growth Factor A/antagonists & inhibitors
;
Visual Acuity/drug effects
;
Vitreous Body
5.Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome.
Sang Joon LEE ; Jung Joo LEE ; Soo Young KIM ; Shin Dong KIM
Korean Journal of Ophthalmology 2009;23(2):132-134
We report a case of ocular ischemic syndrome accompanied by neovascular glaucoma that was successfully treated with Bevacizumab. A 70-year-old male patient diagnosed with neovascular glaucoma of the left eye 3-4 years prior complained of continuous left eye pain and declining visual acuity despite receiving the latest treatment methods. At the time of admission the patient had no light perception in the left eye and his intraocular pressure was 30 mmHg. Anterior segment and fundus examinations revealed neovascularization of the iris and stenosis of the retinal vessel. Hypofluorescence of the choroid and retinal vessels was observed on fluorescence fundus angiography. Left internal carotid artery stenosis was observed on a brain MRI. Despite being treated with eye solution and oral medication, intraocular pressure was not controlled. After 7 days, we performed an intravitreal Bevacizumab 1.25 mg/0.05mL injection. One day after the intravitreal Bevacizumab injection, the neovascularization had nearly regressed and intraocular pressure was 30 mmHg. Intravitreal Bevacizumab injection produced regression of neovascularization and proved effective for treatment of neovascular glaucoma in this case of ocular ischemic syndrome.
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Carotid Stenosis/*complications/diagnosis
;
Diagnosis, Differential
;
Eye/*blood supply
;
Fluorescein Angiography
;
Fundus Oculi
;
Glaucoma, Neovascular/diagnosis/*drug therapy/etiology
;
Humans
;
Injections
;
Ischemia/*complications/diagnosis
;
Magnetic Resonance Angiography
;
Male
;
Vascular Endothelial Growth Factor A
;
Vitreous Body
6.Intravitreal Bevacizumab (Avastin) Treatment of Neovascular Glaucoma in Ocular Ischemic Syndrome.
Sang Joon LEE ; Jung Joo LEE ; Soo Young KIM ; Shin Dong KIM
Korean Journal of Ophthalmology 2009;23(2):132-134
We report a case of ocular ischemic syndrome accompanied by neovascular glaucoma that was successfully treated with Bevacizumab. A 70-year-old male patient diagnosed with neovascular glaucoma of the left eye 3-4 years prior complained of continuous left eye pain and declining visual acuity despite receiving the latest treatment methods. At the time of admission the patient had no light perception in the left eye and his intraocular pressure was 30 mmHg. Anterior segment and fundus examinations revealed neovascularization of the iris and stenosis of the retinal vessel. Hypofluorescence of the choroid and retinal vessels was observed on fluorescence fundus angiography. Left internal carotid artery stenosis was observed on a brain MRI. Despite being treated with eye solution and oral medication, intraocular pressure was not controlled. After 7 days, we performed an intravitreal Bevacizumab 1.25 mg/0.05mL injection. One day after the intravitreal Bevacizumab injection, the neovascularization had nearly regressed and intraocular pressure was 30 mmHg. Intravitreal Bevacizumab injection produced regression of neovascularization and proved effective for treatment of neovascular glaucoma in this case of ocular ischemic syndrome.
Aged
;
Angiogenesis Inhibitors/*administration & dosage
;
Antibodies, Monoclonal/*administration & dosage
;
Carotid Stenosis/*complications/diagnosis
;
Diagnosis, Differential
;
Eye/*blood supply
;
Fluorescein Angiography
;
Fundus Oculi
;
Glaucoma, Neovascular/diagnosis/*drug therapy/etiology
;
Humans
;
Injections
;
Ischemia/*complications/diagnosis
;
Magnetic Resonance Angiography
;
Male
;
Vascular Endothelial Growth Factor A
;
Vitreous Body